Genmab — December 2020
-
Dr Mark Wildgust: Updated APOLLO Trial Results Confirm Daratumumab Safety in Multiple Myeloma https://www.ajmc.com/view/dr-mark-wildgust-updated-apollo-trial-results-confirm-daratumumab-safety-in-multiple-myeloma - ONLY
5% of patients had infusion-related reactions in the APOLLO study, and all of those were grade 1/grade 2. So real confirmation that subcu dara is well tolerated. -
https://genmab-at-ash-2020.com/ genmab-at-ash-2020
-
a bit strange when you look at the pipeline, poster on the right or https://virtualboothdemo.s3.amazonaws.com/Genmab/Content/PDFs/ash/I FINAL PIPELINE.pdf , it shows HexaBody CD38 in development phase I/II
-
-
this is where i think we will be able to see everything, Materials will be available on a rolling basis as soon as individual embargoes are lifted. Dara has some lifted already https://www.oncologysciencehub.com/ash2020/
-
Updated Phase 1 Results of Teclistamab https://www.oncologysciencehub.com/ash2020/bispecifics/garfall/#slides
-
Nina Shah synes om Teclistamab https://twitter.com/ninashah33/status/1335327442563596289?s=21
-
Mange lignende kommentarer på Twitter, alle positive og „big advantage compared to CAR-T“
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind